Advertisement
Advertisement
PRE
Prenetics Global Limited Class A Ordinary Share
18.26
USDSponsored
+0.40
+2.24%
Aug 07, 15:58 UTC -4
Closed
After-Market
18.54
+0.28
+1.55%
PRE Earnings Reports
Positive Surprise Ratio
PRE beat 6 of 14 last estimates.
43%
Next Report
Date of Next Report
Sep 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$49.41M
/-$0.71
Implied change from Q1 26 (Revenue/ EPS)
+37.42%
/-55.90%
Implied change from Q2 25 (Revenue/ EPS)
+179.46%
/-24.47%
Prenetics Global Limited Class A Ordinary Share earnings per share and revenue
On Jun 10, 2026, PRE reported earnings of -1.61 USD per share (EPS) for Q1 26, missing the estimate of -1.10 USD, resulting in a -45.36% surprise. Revenue reached 35.95 million, compared to an expected 36.73 million, with a -2.10% difference. The market reacted with a +0.11% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 2 analysts forecast an EPS of -0.71 USD, with revenue projected to reach 49.41 million USD, implying an decrease of -55.90% EPS, and increase of 37.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Prenetics Global Limited Class A Ordinary Share's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Prenetics Global Limited Class A Ordinary Share reported EPS of -$1.61, missing estimates by -45.36%, and revenue of $35.95M, -2.1% below expectations.
How did the market react to Prenetics Global Limited Class A Ordinary Share's Q1 2026 earnings?
The stock price moved up 0.11%, changed from $17.57 before the earnings release to $17.59 the day after.
When is Prenetics Global Limited Class A Ordinary Share expected to report next?
The next earning report is scheduled for Sep 10, 2026.
What are the forecasts for Prenetics Global Limited Class A Ordinary Share's next earnings report?
Based on 2
analysts, Prenetics Global Limited Class A Ordinary Share is expected to report EPS of -$0.71 and revenue of $49.41M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement